NutriStack
Alpha-Lipoic Acid and Semaglutide, a caution.
Alpha-lipoic acid (ALA) improves insulin sensitivity and lowers blood glucose by upregulating glucose transporters GLUT1 and GLUT4 in skeletal muscle. When combined with semaglutide's glucose-dependent insulin secretion, the additive glucose-lowering effect increases hypoglycemia risk. Additionally, rare cases of insulin autoimmune syndrome (IAS) have been reported with ALA, where it can modify insulin structure through disulfide bond cleavage, triggering autoantibody production.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Alpha-Lipoic Acid and Semaglutide
- Pair type
- Caution
- Evidence (highest tier)
- Moderate
- Source citations
- 3 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Moderate evidence
Caution
What is happening. Alpha-lipoic acid (ALA) improves insulin sensitivity and lowers blood glucose by upregulating glucose transporters GLUT1 and GLUT4 in skeletal muscle. When combined with semaglutide's glucose-dependent insulin secretion, the additive glucose-lowering effect increases hypoglycemia risk. Additionally, rare cases of insulin autoimmune syndrome (IAS) have been reported with ALA, where it can modify insulin structure through disulfide bond cleavage, triggering autoantibody production.
Mechanism. ALA mimics insulin action by stimulating the PI3K/Akt signaling cascade, upregulating GLUT1 and GLUT4 translocation from the Golgi body to the cell membrane, and enhancing glucose uptake in skeletal muscle. Combined with semaglutide's GLP-1-mediated insulin secretion and glucagon suppression, additive glucose reduction occurs.
Recommendation. Use caution when combining alpha-lipoic acid with semaglutide. Monitor blood glucose more frequently, especially when initiating ALA supplementation. Start with lower ALA doses (300 mg/day) and titrate slowly. Report symptoms of hypoglycemia promptly to your healthcare provider.
Sources (3)
- Ansar H et al. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J. 2011;32(6):584-588. PMID 21666939
- Hsieh RY, Huang IC, Chen C, Sung JY. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients. 2023. PMID 37630823
- An P, Wan S, Luo Y, Luo J et al.. Micronutrient Supplementation to Reduce Cardiovascular Risk. Journal of the American College of Cardiology. 2022. PMID 36480969
Stack Score
How this pair moves the number.
Effect on the composite score
If both Alpha-Lipoic Acid and Semaglutide are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.